Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Acerus Pharmaceuticals Corporation, often referred to simply as Acerus, is a Canadian biopharmaceutical company headquartered in Ontario, Canada. Founded in 2006, Acerus focuses on developing innovative therapeutic solutions primarily in the fields of men's health and hormone replacement therapy.
The company has made significant strides with its flagship product, Natesto, a unique nasal testosterone replacement therapy that offers a convenient alternative to traditional methods. Acerus is committed to addressing unmet medical needs, positioning itself as a leader in the niche market of hormone therapies.
With a strong emphasis on research and development, Acerus continues to expand its portfolio and enhance its market presence, striving to improve the quality of life for patients worldwide.
-21 vs industry average
Acerus Pharmaceuticals Corporation’s score of 21 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Acerus Pharmaceuticals Corporation yet.
Acerus Pharmaceuticals Corporation, headquartered in Canada, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Acerus may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time.
In the context of the pharmaceutical industry, many companies are increasingly adopting science-based targets and sustainability initiatives to address climate change. However, without specific emissions data or commitments, it is unclear how Acerus Pharmaceuticals aligns with these industry trends. As the company moves forward, establishing measurable climate goals could enhance its environmental responsibility and align it with broader industry standards.
No climate goals have been disclosed for Acerus Pharmaceuticals Corporation yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more